Planned intervention: On Wednesday April 3rd 05:30 UTC Zenodo will be unavailable for up to 2-10 minutes to perform a storage cluster upgrade.
Published May 12, 2021 | Version v1
Journal article Open

ADVANCES IN THE MANAGEMENT OF DYSLIPIDEMIA

Description

Introduction: Dyslipidemia mainly refers to a disbalance of any form of lipid in the body. Any disbalance of lipid in the body puts the body at a higher risk of coronary and peripheral artery diseases. With the discovery of statins, there has been a huge revolution in the treatment of dyslipidemias. They have shown evidence of reduced levels of LDL with statin leading to a reduction in evidence of CVD.

Aim of work: This review aims at discussing the various therapies and new management strategies developed for managing dyslipidemias associated with CVD or Chronic kidney diseases.

Methodology: The review is a comprehensive research of PUBMED, Google Scholar, and WHO official page from the year 2010 to 2021

Conclusion: Dyslipidemias tend to increase the patients' risk for major cardiovascular events, which can lead to a higher mortality rate in patients with existing cardiac or kidney disorders. There has been an increased interest in the treatment of dyslipidemias, and various genetic therapies and novel medication, including plant-based proteins, have shown a major breakthrough in the management of dyslipidemias. These novel therapies have proven to be a good adjunct to conventional treatment strategies and hence should be tested more thoroughly.

Keywords: Dyslipidemias, Cardiovascular disease, Apolipoproteins, Chronic kidney disease.

Files

17.Advances in management of dyslipidemia.pdf

Files (542.6 kB)

Name Size Download all
md5:9465cfded41c22cb1e1b092c9875bac0
542.6 kB Preview Download